Replimune Group (NASDAQ:REPL) Shares Break Above 50 Day Moving Average – Here’s What Happened

Replimune Group, Inc. (NASDAQ:REPL)’s stock price passed above its 50-day moving average during trading on Wednesday. The stock has a 50-day moving average of $13.46 and traded as high as $16.75. Replimune Group shares last traded at $16.06, with a volume of 7,281,109 shares trading hands.

Analysts Set New Price Targets

REPL has been the topic of several analyst reports. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Replimune Group in a research report on Monday, October 5th. JPMorgan Chase & Co. increased their price objective on Replimune Group from $20.00 to $21.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 26th. Weiss Ratings lowered Replimune Group from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, August 11th. Leerink Partners raised their target price on Replimune Group from $19.00 to $31.00 and gave the stock an “outperform” rating in a research note on Thursday. Finally, Wolfe Research upgraded Replimune Group to an “outperform” rating in a research report on Tuesday, August 4th. One equities research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has given a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat.com, Replimune Group has a consensus rating of “Moderate Buy” and an average price target of $14.33.

Replimune Group Stock Up 1.3%

The company has a debt-to-equity ratio of 0.59, a quick ratio of 5.23 and a current ratio of 7.11. The business has a 50 day moving average price of $13.58 and a 200-day moving average price of $9.35.

Replimune Group (NASDAQ:REPL) last announced its quarterly earnings data on Wednesday, October 28th. The company reported ($0.54) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.78) by $0.24. On average, equities research analysts expect that Replimune Group, Inc. will post -2.74 earnings per share for the current year.

Insider Activity at Replimune Group

In other news, CFO Emily Hill sold 9,256 shares of the company’s stock in a transaction on Monday, August 17th. The shares were sold at an average price of $14.28, for a total transaction of $132,175.68. Following the transaction, the chief financial officer directly owned 215,852 shares of the company’s stock, valued at $3,082,366.56. This represents a 4.11% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Konstantinos Xynos sold 11,447 shares of the stock in a transaction dated Monday, August 10th. The shares were sold at an average price of $12.97, for a total transaction of $148,467.59. Following the completion of the transaction, the insider owned 224,215 shares of the company’s stock, valued at $2,908,068.55. This represents a 4.86% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 79,124 shares of company stock valued at $1,038,364 over the last 90 days. Company insiders own 5.40% of the company’s stock.

Institutional Trading of Replimune Group

A number of institutional investors have recently added to or reduced their stakes in the stock. BlackRock Inc. acquired a new stake in Replimune Group in the second quarter valued at $99,171,000. Montanova Capital LLC increased its position in shares of Replimune Group by 4.0% in the second quarter. Montanova Capital LLC now owns 4,389,836 shares of the company’s stock valued at $48,595,000 after buying an additional 168,000 shares in the last quarter. Opaleye Management Inc. purchased a new position in shares of Replimune Group in the second quarter valued at $15,332,000. Dimensional Fund Advisors LP raised its stake in shares of Replimune Group by 1.9% during the 1st quarter. Dimensional Fund Advisors LP now owns 1,140,099 shares of the company’s stock worth $8,719,000 after buying an additional 20,742 shares during the last quarter. Finally, EcoR1 Capital LLC acquired a new position in shares of Replimune Group during the 1st quarter worth $7,650,000. Hedge funds and other institutional investors own 92.53% of the company’s stock.

Replimune Group Company Profile

Replimune Group, Inc is a clinical-stage biotechnology company developing cancer immunotherapies designed to stimulate the immune system to recognize and attack tumors. The company’s approach focuses on oncolytic immunotherapy, using genetically engineered viruses intended to selectively infect and destroy tumor cells while also activating broader antitumor immune responses.

Replimune’s lead product candidate is RP1, also known as vusolimogene oderparepvec, an engineered oncolytic herpes simplex virus type 1 designed to replicate within tumors and promote systemic immune activity.